Effectiveness of ertapenem for treatment of infections in children: An evidence mapping and meta-analysis
ObjectivesTo assess and summarize current evidence on the effectiveness and safety of ertapenem for treatment of childhood infections, in consideration of high infection prevalence in children and wide use of ertapenem.MethodsThe following 8 databases were searched on 13th May 2021: Web of Science,...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Pediatrics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2022.982179/full |
| _version_ | 1797956696637702144 |
|---|---|
| author | Ruiqiu Zhao Xiaoru Long Jiangxia Wang Jing Zhu Cong Liu Tingting Shang Zhenzhen Zhang Engels Obi Lynda Osadebe Yue Kang Jie Liu Xiaodi Chen Hongmei Xu |
| author_facet | Ruiqiu Zhao Xiaoru Long Jiangxia Wang Jing Zhu Cong Liu Tingting Shang Zhenzhen Zhang Engels Obi Lynda Osadebe Yue Kang Jie Liu Xiaodi Chen Hongmei Xu |
| author_sort | Ruiqiu Zhao |
| collection | DOAJ |
| description | ObjectivesTo assess and summarize current evidence on the effectiveness and safety of ertapenem for treatment of childhood infections, in consideration of high infection prevalence in children and wide use of ertapenem.MethodsThe following 8 databases were searched on 13th May 2021: Web of Science, Embase via Ovid SP, PubMed, The Cochrane Library (CENTRAL), Chinese BioMedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), VIP and Wanfang. The primary outcome was treatment success rate. Risk ratios (RRs) and 95% confidence interval (CI) were estimated using random-effect models. Subgroup analysis was conducted where heterogeneity was found.ResultsFifteen studies (8 randomized controlled trials, 1 observational comparative study, and 6 before and after studies) involving 2,528 patients were included in the final review. Ertapenem had similar treatment success rates with β-lactam antibiotics [relative risk (RR) = 1.08, 95% CI: 0.99–1.19]. In a subgroup analysis, similar efficacy (RR = 1.08, 95% CI: 0.97–1.20) between ertapenem and other carbapenems. Compared with β-lactam antibiotics, ertapenem did not increase the risk of any adverse events (RR = 1.02, 95%CI: 0.71–1.48), drug-related diarrhea (all non-Asian children, RR = 0.62, 95%CI: 0.31–1.25), or injection site pain (all non-Asian children, RR = 1.66, 95%CI: 0.59–4.68). Subgroup analysis showed no obvious difference between ertapenem group and carbapenems or non-carbapenems group on risk of adverse events.ConclusionOur findings suggest that ertapenem is effective and safe in treatment for children with infection. Further comparative real-world data is needed to supplement clinical evidence on the overall benefits of ertapenem in this population. |
| first_indexed | 2024-04-10T23:52:55Z |
| format | Article |
| id | doaj.art-dc67dd0e093c40fa9d23b8451a601d8b |
| institution | Directory Open Access Journal |
| issn | 2296-2360 |
| language | English |
| last_indexed | 2024-04-10T23:52:55Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pediatrics |
| spelling | doaj.art-dc67dd0e093c40fa9d23b8451a601d8b2023-01-10T15:48:52ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602022-10-011010.3389/fped.2022.982179982179Effectiveness of ertapenem for treatment of infections in children: An evidence mapping and meta-analysisRuiqiu Zhao0Xiaoru Long1Jiangxia Wang2Jing Zhu3Cong Liu4Tingting Shang5Zhenzhen Zhang6Engels Obi7Lynda Osadebe8Yue Kang9Jie Liu10Xiaodi Chen11Hongmei Xu12Chongqing Key Laboratory of Child Infection and Immunity, Chongqing Key Laboratory of Pediatrics, Ministry of Education Key Laboratory of Child Development and Disorders, Department of Infectious Diseases of Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, ChinaChongqing Key Laboratory of Child Infection and Immunity, Chongqing Key Laboratory of Pediatrics, Ministry of Education Key Laboratory of Child Development and Disorders, Department of Infectious Diseases of Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, ChinaChongqing Key Laboratory of Child Infection and Immunity, Chongqing Key Laboratory of Pediatrics, Ministry of Education Key Laboratory of Child Development and Disorders, Department of Infectious Diseases of Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, ChinaChongqing Key Laboratory of Child Infection and Immunity, Chongqing Key Laboratory of Pediatrics, Ministry of Education Key Laboratory of Child Development and Disorders, Department of Infectious Diseases of Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, ChinaChongqing Key Laboratory of Child Infection and Immunity, Chongqing Key Laboratory of Pediatrics, Ministry of Education Key Laboratory of Child Development and Disorders, Department of Infectious Diseases of Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, ChinaChongqing Key Laboratory of Child Infection and Immunity, Chongqing Key Laboratory of Pediatrics, Ministry of Education Key Laboratory of Child Development and Disorders, Department of Infectious Diseases of Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, ChinaChongqing Key Laboratory of Child Infection and Immunity, Chongqing Key Laboratory of Pediatrics, Ministry of Education Key Laboratory of Child Development and Disorders, Department of Infectious Diseases of Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, ChinaMerck & Co., Inc., Rahway, NJ, United StatesMerck & Co., Inc., Rahway, NJ, United StatesMRL Global Medical Affairs, MSD China, Shanghai, ChinaMRL Global Medical Affairs, MSD China, Shanghai, ChinaMRL Global Medical Affairs, MSD China, Shanghai, ChinaChongqing Key Laboratory of Child Infection and Immunity, Chongqing Key Laboratory of Pediatrics, Ministry of Education Key Laboratory of Child Development and Disorders, Department of Infectious Diseases of Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, ChinaObjectivesTo assess and summarize current evidence on the effectiveness and safety of ertapenem for treatment of childhood infections, in consideration of high infection prevalence in children and wide use of ertapenem.MethodsThe following 8 databases were searched on 13th May 2021: Web of Science, Embase via Ovid SP, PubMed, The Cochrane Library (CENTRAL), Chinese BioMedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), VIP and Wanfang. The primary outcome was treatment success rate. Risk ratios (RRs) and 95% confidence interval (CI) were estimated using random-effect models. Subgroup analysis was conducted where heterogeneity was found.ResultsFifteen studies (8 randomized controlled trials, 1 observational comparative study, and 6 before and after studies) involving 2,528 patients were included in the final review. Ertapenem had similar treatment success rates with β-lactam antibiotics [relative risk (RR) = 1.08, 95% CI: 0.99–1.19]. In a subgroup analysis, similar efficacy (RR = 1.08, 95% CI: 0.97–1.20) between ertapenem and other carbapenems. Compared with β-lactam antibiotics, ertapenem did not increase the risk of any adverse events (RR = 1.02, 95%CI: 0.71–1.48), drug-related diarrhea (all non-Asian children, RR = 0.62, 95%CI: 0.31–1.25), or injection site pain (all non-Asian children, RR = 1.66, 95%CI: 0.59–4.68). Subgroup analysis showed no obvious difference between ertapenem group and carbapenems or non-carbapenems group on risk of adverse events.ConclusionOur findings suggest that ertapenem is effective and safe in treatment for children with infection. Further comparative real-world data is needed to supplement clinical evidence on the overall benefits of ertapenem in this population.https://www.frontiersin.org/articles/10.3389/fped.2022.982179/fullchildreninfectionertapenemefficacysafety |
| spellingShingle | Ruiqiu Zhao Xiaoru Long Jiangxia Wang Jing Zhu Cong Liu Tingting Shang Zhenzhen Zhang Engels Obi Lynda Osadebe Yue Kang Jie Liu Xiaodi Chen Hongmei Xu Effectiveness of ertapenem for treatment of infections in children: An evidence mapping and meta-analysis Frontiers in Pediatrics children infection ertapenem efficacy safety |
| title | Effectiveness of ertapenem for treatment of infections in children: An evidence mapping and meta-analysis |
| title_full | Effectiveness of ertapenem for treatment of infections in children: An evidence mapping and meta-analysis |
| title_fullStr | Effectiveness of ertapenem for treatment of infections in children: An evidence mapping and meta-analysis |
| title_full_unstemmed | Effectiveness of ertapenem for treatment of infections in children: An evidence mapping and meta-analysis |
| title_short | Effectiveness of ertapenem for treatment of infections in children: An evidence mapping and meta-analysis |
| title_sort | effectiveness of ertapenem for treatment of infections in children an evidence mapping and meta analysis |
| topic | children infection ertapenem efficacy safety |
| url | https://www.frontiersin.org/articles/10.3389/fped.2022.982179/full |
| work_keys_str_mv | AT ruiqiuzhao effectivenessofertapenemfortreatmentofinfectionsinchildrenanevidencemappingandmetaanalysis AT xiaorulong effectivenessofertapenemfortreatmentofinfectionsinchildrenanevidencemappingandmetaanalysis AT jiangxiawang effectivenessofertapenemfortreatmentofinfectionsinchildrenanevidencemappingandmetaanalysis AT jingzhu effectivenessofertapenemfortreatmentofinfectionsinchildrenanevidencemappingandmetaanalysis AT congliu effectivenessofertapenemfortreatmentofinfectionsinchildrenanevidencemappingandmetaanalysis AT tingtingshang effectivenessofertapenemfortreatmentofinfectionsinchildrenanevidencemappingandmetaanalysis AT zhenzhenzhang effectivenessofertapenemfortreatmentofinfectionsinchildrenanevidencemappingandmetaanalysis AT engelsobi effectivenessofertapenemfortreatmentofinfectionsinchildrenanevidencemappingandmetaanalysis AT lyndaosadebe effectivenessofertapenemfortreatmentofinfectionsinchildrenanevidencemappingandmetaanalysis AT yuekang effectivenessofertapenemfortreatmentofinfectionsinchildrenanevidencemappingandmetaanalysis AT jieliu effectivenessofertapenemfortreatmentofinfectionsinchildrenanevidencemappingandmetaanalysis AT xiaodichen effectivenessofertapenemfortreatmentofinfectionsinchildrenanevidencemappingandmetaanalysis AT hongmeixu effectivenessofertapenemfortreatmentofinfectionsinchildrenanevidencemappingandmetaanalysis |